S. Hirai

发表

Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.

S. Ferrone, G. Wong, A. Mittelman, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.

S. Ferrone, A. Mittelman, Z. Chen, 1994, Cancer research.

Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma.

S. Ferrone, T. Kageshita, A. Mittelman, 1993, Pharmacology & therapeutics.

Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma.

H. Inoko, H. Nakagawa, M. Ichihashi, 1997, Tissue antigens.

Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies

S. Ferrone, T. Kageshita, S. Hirai, 1993, The Journal of dermatology.

αvβ3 expression on blood vessels and melanoma cells in primary lesions; differential association with tumor progression and clinical prognosis

S. Ferrone, T. Kageshita, T. Ono, 2000, Cancer Immunology, Immunotherapy.

Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions.

S. Ferrone, T. Kageshita, K. Takatsuki, 1992, Cancer research.

Antigenic profile of mucosal melanoma lesions

S. Ferrone, T. Kageshita, T. Ono, 1994, International journal of cancer.

Clinical course of atopic dermatitis in Japanese patients.

T. Kageshita, T. Ono, S. Hirai, 1998, Journal of dermatological science.

Soluble intercellular adhesion molecule‐1 and soluble E‐selectin levels in patients with atopic dermatitis

T. Kageshita, T. Ono, T. Ono, 1996, The British journal of dermatology.

Human high molecular weight‐melanoma associated antigen mimicry by mouse anti‐idiotypic MAb MK2‐23. Immunohistochemical analysis of the reactivity of anti‐anti‐idiotypic MAb with surgically removed melanoma lesions

S. Ferrone, T. Kageshita, T. Ono, 2006, International journal of cancer.

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

D. Hicklin, S. Ferrone, T. Kageshita, 1999, The American journal of pathology.

Association between sialyl Lewis(a) expression and tumor progression in melanoma.

T. Kageshita, T. Ono, N. Hanai, 1995, Cancer research.

Differential Expression of MART‐1 in Primary and Metastatic Melanoma Lesions

T. Kageshita, Y. Kawakami, T. Ono, 1997, Journal of immunotherapy.

Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen.

S. Ferrone, Z. Chen, C. Liu, 1993, Cancer research.

Differential clinical significance of αvB3 expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes

S. Ferrone, T. Kageshita, T. Ono, 2000 .

Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein.

T. Kageshita, T. Ono, S. Hirai, 1999, Melanoma research.

Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.

T. Kageshita, T. Ono, M. Hidaka, 1992, Japanese Journal of Clinical Oncology.

Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis.

S. Ferrone, T. Kageshita, T. Ono, 2000, Cancer immunology, immunotherapy : CII.